JonesTrading Highlights Differentiated Pipeline at Atai Beckley N.V. (ATAI)

Atai Beckley N.V. (NASDAQ:ATAI) is among the Best Get Rich Fast Stocks to Buy Right Now. On December 23, Justin Walsh from JonesTrading initiated coverage on Atai Beckley N.V. (NASDAQ:ATAI) with a ‘Buy’ rating and a price target of $16, according to TheFly. This translates to an upside potential of nearly 282%.

According to the firm, the company’s psychedelic and empathogenic drugs pipeline presents “differentiated opportunities” across large neuropsychiatric indications. Walsh believes Atai Beckley N.V. (NASDAQ:ATAI) will benefit from the ongoing trends supporting the development of drugs in these classes. The short half-lives of the company’s BPL-003 and VLS-01 will “allow their use in treatment-resistant depression (TRD),” after Johnson & Johnson’s SPRAVATO (esketamine) commercial approach.

While acknowledging the broad TRD market’s potential to accommodate multiple successful therapies, JonesTrading noted the strength of the company’s lead compounds, led by SPRAVATO. The analyst remains hopeful about the effectiveness of the company’s third clinical asset, EMP-01, in social anxiety disorder (SAD).

Earlier on December 11, Atai Beckley N.V. (NASDAQ:ATAI) announced the approval of a new patent for EMP-01, an oral R-MDMA solution for social anxiety disorder, by the United States Patent and Trademark Office. As said by Srinivas Rao, the Chief Executive Officer and Co-founder,

“This patent grant reinforces the strength of our science and our long-term commitment to building durable, defensible innovation.”

Atai Beckley N.V. (NASDAQ:ATAI), based in Amstelveen, The Netherlands, is a clinical-stage biopharmaceutical company specializing in treatments for mental health. Founded in 2018, the company is committed to transforming patient outcomes.

While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.